Literature DB >> 22311348

Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure.

Christoph Birner1, Oliver Husser, Andreas Jeron, Munhie Rihm, Sabine Fredersdorf, Markus Resch, Peter Schmid, Dierk Endemann, Günter Riegger, Andreas Luchner.   

Abstract

Heart failure causes electrophysiological changes in the heart. Downregulation of repolarizing K+-currents leads to a prolongation of the cardiac action potential. Nevertheless, little is known about the differential expression of atrial and ventricular K+-channels in the failing heart. Ten rabbits underwent progressive rapid right ventricular pacing for 30 days. Digitized ECGs and echocardiograms were obtained. Left ventricular and left atrial tissue was harvested and mRNA levels of BNP, Kv4.3, rERG, Kv1.5, and KvLQT1 were measured by real time PCR. Experimental heart failure was characterized by left ventricular dilatation (13 ± 1 mm vs. 9 ± 1, p < .001), depressed fractional shortening (25 ± 5% vs. 40 ± 4, p < .001), and left atrial remodeling with increased diameter (16 mm ± 2 vs. 12 ± 1, p = .002) and weight (1.3 g ± 0.2 vs. 0.5 ± 0.1, p = .01). A prolongation of P-wave (44 ± 5 ms vs. 40 ± 4, p = .001) and PQ-interval (73 ± 10 ms vs. 66 ± 9, p = .009) occurred. In heart failure, BNP mRNA levels showed a significant upregulation in the left ventricle and atrium (1.83 AU ±1.31 vs. 0.67 ± 0.65, p < .05 and 7.16 AU ±1.76 vs. 0.77 ± 0.48, p < .05). Left ventricular Kv1.5 mRNA was reduced by 50% (p < .001) and KvLQT1 was reduced by 70% (p < .001). rERG and Kv4.3 mRNA were unchanged (n = ns). In contrast, left atrial Kv4.3 and KvLQT1 were reduced by 70% (p < .001), whereas rERG and Kv1.5 were unchanged (p = ns). Significant correlations were present between BNP and K+-channel expressions. Heart failure is characterized by significant changes in the gene expression of repolarizing K+-currents with a differential atrial and ventricular pattern. These molecular changes occur together with changes in cardiac function, geometry, conduction, and BNP expression and provide a functional basis for electrical vulnerability in heart failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311348     DOI: 10.1007/s00210-011-0723-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

Review 1.  Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.

Authors:  S Nattel; L Yue; Z Wang
Journal:  Cell Physiol Biochem       Date:  1999

2.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation.

Authors:  L Yue; J Feng; R Gaspo; G R Li; Z Wang; S Nattel
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

3.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

Review 4.  Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets.

Authors:  Joachim R Ehrlich; Stanley Nattel; Stefan H Hohnloser
Journal:  J Cardiovasc Electrophysiol       Date:  2002-04

5.  Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation.

Authors:  D R Van Wagoner; A L Pond; P M McCarthy; J S Trimmer; J M Nerbonne
Journal:  Circ Res       Date:  1997-06       Impact factor: 17.367

6.  Molecular mechanisms underlying K+ current downregulation in canine tachycardia-induced heart failure.

Authors:  Fadi G Akar; Richard C Wu; George J Juang; Yanli Tian; Mirka Burysek; Deborah Disilvestre; Wei Xiong; Antonis A Armoundas; Gordon F Tomaselli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-28       Impact factor: 4.733

Review 7.  What causes sudden death in heart failure?

Authors:  Gordon F Tomaselli; Douglas P Zipes
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

8.  Depressed transient outward and calcium currents in dilated human atria.

Authors:  B L Le Grand; S Hatem; E Deroubaix; J P Couétil; E Coraboeuf
Journal:  Cardiovasc Res       Date:  1994-04       Impact factor: 10.787

9.  Myocyte electrophysiological properties following the development of supraventricular tachycardia-induced cardiomyopathy.

Authors:  R Mukherjee; K W Hewett; F G Spinale
Journal:  J Mol Cell Cardiol       Date:  1995-06       Impact factor: 5.000

10.  Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density.

Authors:  S Kääb; J Dixon; J Duc; D Ashen; M Näbauer; D J Beuckelmann; G Steinbeck; D McKinnon; G F Tomaselli
Journal:  Circulation       Date:  1998-10-06       Impact factor: 29.690

View more
  3 in total

1.  Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.

Authors:  Christoph Birner; Coskun Ulucan; Mona Bratfisch; Tobias Götz; Alexander Dietl; Frank Schweda; Günter A Riegger; Andreas Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-16       Impact factor: 3.000

2.  Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.

Authors:  Laura Grois; Julian Hupf; Jörg Reinders; Josef Schröder; Alexander Dietl; Peter M Schmid; Carsten Jungbauer; Markus Resch; Lars S Maier; Andreas Luchner; Christoph Birner
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

3.  Chronic myocardial infarction promotes atrial action potential alternans, afterdepolarizations, and fibrillation.

Authors:  Sarah Kettlewell; Francis L Burton; Godfrey L Smith; Antony J Workman
Journal:  Cardiovasc Res       Date:  2013-04-08       Impact factor: 10.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.